Le Lézard
Classified in: Health
Subject: CFG

Advisory - Unauthorized "Surfaz-SN Triple Action Cream" seized from Mississauga store may pose serious health risks


OTTAWA, Oct. 18, 2018 /CNW/ -

Issue
Health Canada seized "Surfaz-SN Triple Action Cream"?an unauthorized skin cream promoted for antifungal, antibacterial and anti-inflammatory use?because it is labelled to contain prescription drugs (betamethasone dipropionate and neomycin sulphate). The product was seized from Kaf African Caribbean Market (2642 Liruma Road, Unit 2A) in Mississauga, Ontario. 

Surfaz-SN Triple Action Cream has not been evaluated by Health Canada for safety, effectiveness or quality and may pose serious health risks.

Who is affected

Affected product

What consumers should do

What Health Canada is doing
Health Canada seized the product from the retail location. Should additional retailers or distributors be identified, Health Canada will take appropriate action and inform Canadians as necessary.

Background

Betamethasone dipropionate is a highly potent corticosteroid prescription drug that can be used topically (applied to the skin) to treat inflammatory skin conditions. It should be used only under the supervision of a health care professional. Side effects from topical use include skin irritation and, with prolonged use, skin weakening or deterioration. Topical corticosteroids can be absorbed in sufficient amounts to produce adverse effects, including symptoms of adrenal suppression (low blood pressure, low blood sugar, weight loss, muscle pain, gastrointestinal problems, and severe fatigue) or Cushing's syndrome (high blood pressure, high blood sugar, weight gain, muscle weakness, bone loss, and severe fatigue) depending on how much has been absorbed. Betamethasone dipropionate should not be used by pregnant or nursing women.

Neomycin sulphate is an antibiotic prescription drug and should be used only under the supervision of a health care professional. Side effects include allergic reactions that range from mild skin reactions (itching, rash and hives) to severe, life-threatening allergic reactions (anaphylaxis). Side effects?such as damage to nerve tissue or the central nervous system, inner ear, and organs responsible for hearing and balance, and reduced kidney function?have occurred in patients taking neomycin orally (by mouth) or when applied on the skin to open wounds or damaged skin. As well, when not used as directed, neomycin sulphate could increase the risk of infections resistant to neomycin or other antibiotics. Neomycin sulphate should not be used by pregnant or breastfeeding women unless directed by a healthcare professional.

Stay connected with Health Canada and receive the latest advisories and product recalls.

Également disponible en français

 

SOURCE Health Canada


These press releases may also interest you

at 06:08
The Annual General Meeting of Bioretec Ltd was held on 26 April 2024 in Tampere, Finland. The Annual General Meeting approved the financial statements for the financial year 1 January?31 December 2023 and resolved to discharge the members of the...

at 06:00
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted...

at 06:00
-- Diluted EPS of $2.16; Adjusted Diluted EPS of $2.26 ---- Increases 2024 Full Year Guidance -- 2024 adjusted diluted EPS of $2.26, up over 7% from $2.11 in the first quarter of 2023.Increases 2024 full year adjusted diluted EPS guidance by $0.10 to...

at 06:00
Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first...

at 05:12
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme"). For this purpose, Sobi has prepared a base prospectus, which...

at 04:00
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood pressure screening and promote hypertension prevention, detection,...



News published on and distributed by: